Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;77(2):203-7.
doi: 10.1136/jnnp.2005.072355.

Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001

Affiliations

Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001

J F Owe et al. J Neurol Neurosurg Psychiatry. 2006 Feb.

Abstract

Objective: This study investigated the causes of death among patients with myasthenia gravis (MG), with emphasis on respiratory tract and cardiac disease.

Methods: The Norwegian Cause of Death Register contains information on all deaths among Norwegian citizens. In total, 249 deceased patients with MG were identified (1951-2001). These were compared with 1245 controls deceased in the same period and matched for sex and year of birth.

Results: The death certificates of patients with MG had a significantly higher occurrence of respiratory tract disease as cause of death than controls (28.1% v 20.9%, p = 0.012). The difference was most pronounced for male patients, for patients dying between 30 and 69 years of age, and for deaths occurring before 1996. For cardiac disease there was a significantly lower occurrence among patients with MG than among controls at 50-69 years of age, for both men (19.4% v 52.0%, p = 0.001) and women (14.6% v 29.6%, p = 0.036). Age and year of death were important determinants for the causes of death, but could not account for the differences between the patients with MG and controls.

Conclusions: This study shows that patients with MG dying between 1951 and 1995 had a higher occurrence of respiratory tract disease listed as cause of death than had a matched control group. The lack of difference after 1995 probably reflects improved treatment of MG and its complications. The reduced occurrence of cardiac disease among patients with MG is probably explained by competing factors (respiratory tract disease) causing death.

PubMed Disclaimer

Conflict of interest statement

Competing interests: none

References

    1. Vincent A, Palace J, Hilton‐Jones D. Myasthenia gravis. Lancet 20013572122–2128. - PubMed
    1. Romi F, Skeie G O, Aarli J A.et al Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000247369–375. - PubMed
    1. McConville J, Farrugia M E, Beeson D.et al Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 200455580–584. - PubMed
    1. Lindstrom J. Is “seronegative” MG explained by autoantibodies to MuSK? Neurology 2004621920–1921. - PubMed
    1. Phillips L H, Torner J C. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996471233–1238. - PubMed

Publication types